National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ribociclib (Kisqali®) is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of pre-, peri- and post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine therapy, or in women who have received prior endocrine therapy:

 

NCPE Assessment Process Complete
Rapid review commissioned 11/06/2019
Rapid review completed 11/07/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that ribociclib not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.